IFRX - InflaRx N.V.
| Previous Close | 4.2100 |
| Open | 4.2200 |
| Bid | 4.2400 x 900 |
| Ask | 4.2600 x 800 |
| Day's Range | 4.1600 - 4.2600 |
| 52 Week Range | 0.7760 - 7.2500 |
| Volume | |
| Avg. Volume | 2,503,741 |
| Market Cap | 247.899M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6500 |
| Earnings Date | Aug 03, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.63 |
GlobeNewswireInflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration (FDA) for Gohibic (vilobelimab) for treatment of critically ill COVID-19 patientsGohibic planned to be available to patients in the U.S. within the next few weeksPhase III study with vilobelimab in pyoderma gangrenosum (PG) underway; first patient expected to be enrolled mid-2023Cash, cash equivalents and marketable securities approximately €72.3 million as of March 31, 2023Additional €53.5 million in aggregate pr
Simply Wall St.InflaRx N.V.'s (NASDAQ:IFRX) Profit Outlook
InflaRx N.V. ( NASDAQ:IFRX ) is possibly approaching a major achievement in its business, so we would like to shine...
- GlobeNewswire
InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million
JENA, Germany, April 18, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that, in connection with its previously announced completion of its underwritten public offering of 9,411,765 ordinary shares, the underwriters have fully exercised their option to purchase an additional 1,411,764 ordinary shares at a public offering price of $4.25 pe
- GlobeNewswire
InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares
JENA, Germany, April 14, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has completed its underwritten public offering of 9,411,765 ordinary shares at a public offering price of $4.25 per ordinary share. The aggregate gross proceeds from the offering were approximately $40 million, before deducting the underwriting discount and of
ZacksBiotech Stock Roundup: MRNA Provides Update, KALA, IFRX Surge on Regulatory News
Regulatory and pipeline updates from Moderna (MRNA) and KALA are the key highlights for the biotech sector.
- GlobeNewswire
InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares
JENA, Germany, April 12, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the pricing of its underwritten public offering of 9,411,765 ordinary shares at an offering price of $4.25 per ordinary share. The offering is expected to close on April 14, 2023, subject to the satisfaction of customary closing conditions. The Company has granted the
- GlobeNewswire
InflaRx Announces Public Offering of Ordinary Shares
JENA, Germany, April 11, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has commenced an underwritten public offering of ordinary shares of the Company. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Motley FoolWhy InflaRx Stock Skyrocketed This Week
The biopharmaceutical company's near-term sales outlook has gotten a huge boost following Emergency Use Authorization for one of its drugs.
Motley FoolWhy Shares of InflaRx Are Soaring Wednesday
Shares of InflaRx (NASDAQ: IFRX) were up 48% an hour after the market opened on Wednesday on news the company's COVID-19 therapy was receiving an Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA). The healthcare stock jumped to a 52-week high of $7.25 a share in early trading after the FDA approved an EUA for Gohibic (vilobelimab), a monoclonal anti-human complement factor C5a antibody, to treat hospitalized COVID-19 patients within 48 hours of receiving oxygen through a ventilator or through a heart-lung machine. The EUA is based on the company's successful phase 3 study of the drug on 369 hospitalized patients that showed a 23.9% reduction in the mortality rate compared with placebo.
ZacksInflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment
InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.
- Reuters
UPDATE 1-InflaRx COVID injection gets US FDA's emergency-use authorization
The U.S. Food and Drug Administration (FDA) on Tuesday granted emergency-use authorization to Inflarx NV's monoclonal antibody for the treatment of hospitalized COVID patients when initiated within 48 hours of receiving artificial life support. The injection known as Gohibic targets a part of the immune system that is thought to play a role in the inflammation that leads to COVID-19 disease progression. The data supporting the authorization is based on a late-stage trial which showed that patients treated with Gohibic had a lower risk of death by day 28 and day 60 of treatment compared with a placebo.
- GlobeNewswire
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body's immune responseFDA granted EUA based on Phase III clinical trial results showing a significant relative reduction in 28-day all-cause mortality of 23.9% compared to placebo in critically ill invasively mechanically ventilated COVID-19 patientsInflaRx continues the dialogue with FDA to discuss next steps towards a Biologics License Application submissio
- Simply Wall St.
We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- GlobeNewswire
InflaRx Reports Full Year 2022 Financial and Operating Results
Major progress in development of vilobelimab Phase III study in PG announced following detailed feedback and recommendations from the U.S. Food and Drug Administration (FDA); clinical trial protocol submitted; first patient expected around mid-2023Fast Track and Orphan Drug designations granted for treatment of pyoderma gangrenosum (PG) in the United States and Orphan Drug designation granted in Europe Encouraging results from Phase III study in critically ill COVID-19 patients published in The
- GlobeNewswire
InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients
Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient number between approximately 50 and 100 patientsFDA review of application for emergency use authorization (EUA) of vilobelimab for the treatment of critically ill COVID-19 patients ongoing InflaRx’s management team to host investor and business meetings during JPM Week, January 9 – 12, 2023 in San Franci
- GlobeNewswire
InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19
InflaRx will provide access to certain clinical, manufacturing and regulatory documentation for vilobelimab to facilitate STS’s regulatory filings in ChinaSTS plans to request regulatory approval in China for its own anti-C5a-antibody BDB-001 for the treatment of COVID-19 based on InflaRx’s technology in-licensed by STSInflaRx will receive 10% royalties on net sales of BDB-001 for the treatment of COVID-19 in ChinaSTS to make an additional USD 2.5 million investment in InflaRx at a price of USD
- GlobeNewswire
InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904
Randomized, double-blind, placebo-controlled Phase I trial of orally administered complement inhibitor INF904 initiatedStudy designed as single ascending dose to determine safety, tolerability and pharmacokinetics in healthy volunteersFuture development in complement-mediated chronic diseases JENA, Germany, Nov. 09, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today a
- GlobeNewswire
InflaRx Reports Third Quarter 2022 Financial & Operating Results
Vilobelimab earns Orphan Drug and Fast Track designation for the treatment of critically ill, intubated, mechanically ventilated COVID-19 patients - Emergency Use Authorization (EUA) submitted to U.S. Food and Drug Administration (FDA)PANAMO Phase III study results in severe COVID-19 published in peer-reviewed journal, The Lancet Respiratory Medicine Fast Track designation granted for the treatment of pyoderma gangrenosum by FDACash, cash equivalents and marketable securities of €93.2 million, e
- GlobeNewswire
InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
Company also earns FDA Fast Track designation for vilobelimab to treat critically ill COVID-19 patientsEUA submission based on Phase III results in critically ill COVID-19 patients, recently published in The Lancet Respiratory MedicineRequest for EUA follows encouraging interactions with FDA in Type B meeting“Gohibic” conditionally accepted by FDA as proprietary name for vilobelimab JENA, Germany, Sept. 29, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical
- GlobeNewswire
InflaRx to Present at Upcoming Scientific and Investor Conferences
JENA, Germany, Sept. 09, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at several conferences. H.C. Wainwright 24th Annual Global Investment Conference, New York, NY USA: Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, will provide a general corporate overview and update on Wednesday, September 14th at 9:30 am
- GlobeNewswire
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
The Lancet Respiratory Medicine, a peer-reviewed journal, published the results of the PANAMO trial, one of the largest, global, 1:1 randomized, placebo-controlled Phase III studies conducted in invasively mechanically ventilated, critically ill COVID-19 patientsIn-depth statistical analysis confirms robustness of clinical survival benefit of vilobelimab treatment on 28-day and 60-day all-cause mortalityVilobelimab targets the inflammatory immune response evoked by SARS-CoV-2 infection that caus
- Simply Wall St.
Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
ZacksHere's Why InflaRx N.V. (IFRX) is a Great Momentum Stock to Buy
Does InflaRx N.V. (IFRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
ZacksInflaRx N.V. (IFRX) Upgraded to Buy: What Does It Mean for the Stock?
InflaRx N.V. (IFRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- GlobeNewswire
InflaRx Reports Second Quarter 2022 Financial & Operating Results
Fast Track and Orphan Drug designation for vilobelimab in pyoderma gangrenosum (PG) granted by the FDAPlans to submit EUA with the FDA for vilobelimab in critically ill COVID-19 patients announcedGrant income of €14.4 million realized during the second quarterCash, cash equivalents and marketable securities of €91.8 million, expected to finance operations until year-end 2024 JENA, Germany, Aug. 05, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company d